EMERYVILLE, Calif., Jan. 19, 2016 /PRNewswire/ -- Berkeley Lights, Inc., today announced it has shipped the first instrument incorporating its OptoSelect™ light technology for antibody discovery. This shipment to Amgen marks the beginning of the commercialization of systems in Berkeley Lights' effort to fundamentally transform current microfluidic, fragmented workflows in biopharma, diagnostics and life science research into miniaturized automated nanofluidic workflows that allow parallel manipulation of individual cells and reagents.
Berkeley Lights is the pioneer in opto-nanofluidic biosystems that enable interactive biology at the cellular level. The company's biosystems and nanofluidic chips incorporate its OptoSelect™ visible light technology, which is poised to transform cell line development and antibody discovery for biopharmaceutical companies by enabling workflows to allow clone screening at the single cell level. BLI's biosystems empower researchers to individually select and export cells in real-time based on indicators such as single-cell protein secretion binding and levels, cell surface markers and morphology, through integrated workflows with walk-away operation.
BLI is engaged with several global biopharmaceutical companies to help them enable new workflows for therapeutic antibody discovery and production cell line development. Amgen's Vice President of Research, Philip Tagari, presented information on BLI's OptoSelect™ technology and its application in antibody discovery at the Discovery Summit conference in September 2015.
"Amgen has been an exceptional collaborative partner for Berkeley Lights and it is fitting that Amgen receives the first commercial BLI biosystem in the biopharmaceutical sector," stated Igor Khandros, Ph.D., Berkeley Lights CEO and co-founder. "We are excited to enable Amgen to begin discovering and developing new antibody therapeutics using the BLI biosystem."
About Berkeley Lights, Inc.
Berkeley Lights opto-nanofluidic platforms are enabling interactive biology at the cellular level and empowering scientists and researchers to study and interact with single cells in ways never before possible. Headquartered in Emeryville, California, Berkeley Lights is working with biopharma and biotech companies to facilitate drug discovery and cell line development, and with research institutes on single-cell annotation and genomics. For more information, visit http://www.berkeleylights.com/.
SOURCE Berkeley Lights, Inc.